Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Pancreatic cancer patients offered new treatment

  • 1 Comment

Patients suffering from a rare form of pancreatic cancer have been offered a lifeline that could double their survival chances.

The drug sunitinib is the first treatment to be licensed for pancreatic neuroendocrine tumours (NET) in the last 25 years.

It was approved for the disease by European regulators after tests revealed it increased survival time from 5.5 months to 11.4 months - with no evidence of worsening symptoms.

While full data on overall survival is not available, the trend so far demonstrates that patients on sunitinib have less than half the death rate of those who received a placebo.

Pancreatic NET develops in the insulin-producing islet cells of the pancreas. The disease affects up to 240 people in the UK each year, typically between the ages of 40 and 60.

Dr Juan Valle, University of Manchester and Christie NHS Foundation Trust medical oncologist, said: “After years of working with few treatment options, sunitinib provides new hope for patients living with this difficult to treat disease.”

Sunitinib, sold under the brand name Sutent, is already licensed in the UK for the treatment of advanced kidney cancer.

  • 1 Comment

Readers' comments (1)

  • For those interested in Pancreatic Cancer - have a look at www.pancreaticcanceraction.org

    a charity dedicated to improving the number of people who survive pancreatic cancer

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs